

Free Shipping on All Orders \$75 Or More! (/Lpages/2017/FreeShipping2/index)

MENU



LifeExtension® (/)

Sign In (<https://mycart.lifeextension.com/Login.aspx?s=1>)



Contact (<http://www.lef.org/quest-com.htm>)

My Cart

Keyword or Item#

LIFE EXTENSION MAGAZINE

<< Back to March 2004 (/Magazine/2004/3)

The DHEA Debate

March 2004

COVER STORY

A critical review of clinical and experimental data

x) References

1. Welle S, Jozefowicz R, Statt M. Failure of dehydroepiandrosterone to influence energy and protein metabolism in humans. *J Clin Endocrinol Metab.* 1990 Nov;71(5):1259-64.
2. Villareal DT, Holloszy JO, Kohrt WM. Effects of DHEA replacement on bone mineral density and body composition in elderly women and men. *Clin Endocrinol. (Oxf)* 2000 Nov;53(5):561-8.
3. Kawano H, Yasue H, Kitagawa A, et al. Dehydroepiandrosterone supplementation improves endothelial function and insulin sensitivity in men. *J Clin Endocrinol Metab.* 2003 Jul;88(7):3190-5.
4. Diamond P, Cusan L, Gomez JL, Belanger A, Labrie F. Metabolic effects of 12 month percutaneous dehydroepiandrosterone replacement therapy in postmenopausal women. *J Endocrinol.* 1996; 150:S43-S50.
5. Casson PR, Faquin LC, Stentz FB, et al. Replacement of dehydroepiandrosterone enhances T-lymphocyte insulin binding in postmenopausal women. *Fertil Steril.* 1995 May;63(5):1027-31.
6. Al-Harithy RN. Dehydroepiandrosterone sulfate levels in women; relationship with body mass index, insulin and glucose levels. *Saudi Med J.* 2003; 24(8):837-41.
7. Chiu KM, Schmidt MJ, Havighurst TC, et al. Correlation of serum L-carnitine and dehydroepiandrosterone sulphate levels with age and sex in healthy adults. *Age Ageing.* 1999;28(2):211-6.

De Pergola G. The adipose tissue metabolism: role of testosterone and DHEA. *Int J Obesity.* 2000;24: Suppl 2. S59-S63.



9. Valtysdottir ST, Wide L, Hallgren R. Mental well-being and quality of sexual life in women with primary Sjogren's syndrome are related to circulating dehydroepiandrosterone sulphate. *Ann Rheum Dis.* 2003 Sep;62(9):875-9.
10. Jozuka H, Jozuka E, Takeuchi S, Nishikaze O. Comparison of immunological and endocrinological markers associated with major depression. *J Int Med Res.* 2003 Jan-Feb;31(1):36-41.
11. Schmidt PJ, Murphy JH, Haq N, Danaceau MA, St Clair L. Basal plasma hormone levels in depressed perimenopausal women. *Psychoneuroendocrinology.* 2002 Nov;27(8):907-20.
12. Wolf OT, Neumann O, Hellhammer DH, et al. Effects of a two-week physiological dehydroepiandrosterone substitution on cognitive performance and well-being in healthy elderly women and men. *J Clin Endocrinol Metab.* 1997;82:2363-7.
13. Kudielka BM, Hellhammer J, Hellhammer DH, et al. Sex differences in endocrine and psychological responses to psychosocial stress in healthy elderly subjects and the impact of a two-week dehydroepiandrosterone treatment. *J Clin Endocrinol Metab.* 1998 May;83(5):1756-61.
14. Morales AJ, Nolan JJ, Nelson JC, Yen SS. Effects of a replacement dose of dehydroepiandrosterone in men and women of advancing age. *J Endocrinol Metab.* 1994 Jun;78(6):1360-7.
15. Yen SS, Morales AJ, Khorram O. Replacement of DHEA in aging men and women. *Ann NY Acad Sci.* 1995 Dec 29; 774:128-42.
16. Baulieu EE. Dehydroepiandrosterone (DHEA): a fountain of youth? *J Clin Endocrinol Metab.* 1996 Sep;81(9):3147- 51.
17. van Broekhoven F, Verkes RJ. Neurosteroids in depression: a review. *Psychopharmacology. (Berl).* 2003 Jan;165(2):97-110. Epub 2002 Nov 06.
18. Nadjafi-Triebsch C, Huell M, Burki D, Rohr UD. Progesterone increase under DHEA-substitution in males. *Maturitas.* 2003 Jul 25;45(3):231-5.
19. Arlt W, Callies F, Allolio B. DHEA replacement in women with adrenal insufficiency—pharmacokinetics, bioconversion and clinical effects on well-being, sexuality and cognition. *Endocr Res.* 2000 Nov;26(4):505-11.
20. Wolkowitz OM, Reus VI, Roberts E, et al. Antidepressant and cognition-enhancing effects of DHEA in major depression. *Ann NY Acad Sci.* 1995 Dec 29;774:337-9.
21. Bloch M, Schmidt PJ, Danaceau MA, Adams LF, Rubinow DR. Dehydroepiandrosterone treatment of midlife dysthymia. *Biological Psychiatry.* 1999 Jun 15;45(12):1533-41.
22. Jesse RL, Loesser K, Eich DM, Qian YZ, Hess ML, Nestler JE. Dehydroepiandrosterone inhibits human platelet aggregation in vitro and in vivo. *Ann NY Acad Sci.* 1995 Dec 29;774:281-



Barret-Connor E, Knaw KT, Yen SSC. A prospective study of dehydroepiandrosterone replacement, mortality and cardiovascular disease. *N Engl J Med.* 1986 Dec 11; 315:1519-24.



24. Shono N, Kumagai S, Higaki Y, Nishizumi M, Sasaki H. The relationships of testosterone, estradiol, dehydroepiandrosterone-sulfate and sex hormone-binding globulin to lipid and glucose metabolism in healthy men. *J Atherosclerosis and Thrombosis*. 1996;3(1):45-51.
25. Okamoto K. Relationship between dehydroepiandrosterone sulfate and serum lipid levels in Japanese men. *J Epidemiol*. 1996 Jun;6(2):63-7.
26. Tagawa N, Tamanaka J, Fujinami A, et al. Serum dehydroepiandrosterone, dehydroepiandrosterone sulfate, and pregnenolone sulfate concentrations in patients with hyperthyroidism and hypothyroidism. *Clin Chem*. 2000 Apr; 46(4):523-528.
27. Inaudi P, Massafra C, Bernabei A, Antoni G, D'Antona N. Gonadotropin, prolactin and thyrotropin pituitary secretion after exogenous dehydroepiandrosterone sulfate administration in normal women. *Horm Red*. 1991;35(1):35-40.
28. Tagawa N, Tokano T, Fukata S, et al. Serum concentrations of androstenediol and androstenediol sulfate in patients with hyperthyroidism and hypothyroidism. *Endocr J*. 2001;48:345-54.
29. Vranckx R, Mechighel P, Savu L. Effect of dehydroepiandrosterone on rat thyroxine binding globulin, a protein upregulated during aging. *Ann NY Acad Sci*. 1995 Dec 29; 774:335-6.
30. Bickova M, Tallova J, Hill M, Vanuga A, Putz Z, Tomandl J. Effect of treatment of hypothyroidism on the plasma concentrations of neuroactive steroids and homocysteine. *Clin Chem Lab Med*. 2001; 39:753-7.
31. de Bruin VM, Vieira MC, Rocha MN, Viana GS. Cortisol and dehydroepiandrosterone sulfate plasma levels and their relationship to aging, cognitive function, and dementia. *Brain Cogn*. 2002 Nov;50(2):316-23.
32. Ferrari E, Casarotti D, Muzzoni B, et al. Age-related changes of the adrenal secretory pattern: possible role in pathological brain aging. *Brain Res Brain Res Rev*. 2001 Nov;37(1-3):294-300.
33. Wisniewski TL, Hilton CW, Morse EV, Svec F. The relationship of serum DHEAS and cortisol levels to measures of immune function in Human Immunodeficiency Virus-related illness. *Am J Med Sci*. 1993 Feb; 305(2):79-83.
34. Mattison JA, Lane MA, Roth GS, Ingram DK. Calorie restriction in rhesus monkeys. *Exp Gerontol*. 2003 Jan-Feb; 38(1-2):35-46.
35. Catalina F, Kumar V, Milewich L, Bennett M. Food restriction-like effects of dehydroepiandrosterone: decreased lymphocyte numbers and functions with increased apoptosis. *Proc Soc Exp Biol Med*. 1999 Sep;221(4):326-35.
36. Wang TT, Hursting SD, Perkins SN, Phang JM. Effects of dehydroepiandrosterone and calorie restriction on the Bcl-2/Bax-mediated apoptotic pathway in p53-deficient mice. *Cancer Res*. 1997 Jun 3;116(1):61-9.

Roberts E. The importance of dehydroepiandrosterone sulfate in the blood of primates: a longer and healthier life? *Biochem Pharmacol*. 1999 Feb 15;57(4):329-46.



38. Shock NW, et al, eds. Normal Human Aging: the Baltimore Longitudinal Study on Aging. Washington, DC: US Government Printing Office;1984.
39. Roth GS, Lane MA, Ingram DK, et al. Biomarkers of calorie restriction may predict longevity in humans. *Science*. 2002 Aug 2; 297(5582):811.
40. Ravaglia G, Forti P, Maioli F, et al.. The relationship of dehydroepiandrosterone sulfate (DHEAS) to endocrine-metabolic parameters and functional status in the oldest-old. Results from an Italian study on healthy free-living over-ninety-year- olds. *J Clin Endocrinol Metab*. 1996 Mar;81(3):1173-8.
41. Ravaglia G, Forti P, Maioli F, et al. Determinants of functional status in healthy Italian nonagenarians and centenarians: a comprehensive functional assessment by the instruments of geriatric practice. *J Am Geriatr Soc*. 1997 Oct;45(10):1196-202.
42. van den Beld AW, Lamberts SW. The male climacterium: clinical signs and symptoms of a changing endocrine environment. *Prostate Suppl*. 2000;10:2-8.
43. Yang NC, Jeng KC, Ho WM, Hu ML. ATP depletion is an important factor in DHEA-induced growth inhibition and apoptosis in BV-2 cells. *Life Sci*. 2002 Mar 15;70(17):1979-88.
44. Schulz S, Klann RC, Schonfeld S, Nyce JW. Mechanisms of cell growth inhibition and cell cycle arrest in human colonic adenocarcinoma cells by dehydroepiandrosterone: role of isoprenoid biosynthesis. *Cancer Res*. 1992 Mar 1;52(5):1372-6.
45. Loria RM. Immune up-regulation and tumor apoptosis by androstene steroids. *Steroids*. 2002 Nov;67(12):953-66.
46. Dashtaki R, Whorton AR, Murphy TM, Chitano P, Reed W, Kennedy TP. Dehydroepiandrosterone and analogs inhibit DNA binding of AP-1 and airway smooth muscle proliferation. *J Pharmacol Exp Ther*. 1998 May; 285(2); 876-83.
47. Wang TT, Hursting SD, Perkins SN, Phang JM. Effects of dehydroepiandrosterone and calorie restriction on the Bcl-2/Bax-mediated apoptotic pathway in p53-deficient mice. *Cancer Lett*. 1997 Jun 3;116(1):61-9.
48. Aoki K, Nakajima A, Mukasa K, Osawa E, Mori Y, Sekihara H. Prevention of diabetes, hepatic injury, and colon cancer with dehydroepiandrosterone. *J Steroid Biochem Mol Biol*. 2003 Jun;85(2-5):469- 72.
49. Marx C, Petros S, Bornstein SR, et al. Adrenocortical hormones in survivors and nonsurvivors of severe sepsis: diverse time course of dehydroepiandrosterone, dehydroepiandrosterone-sulfate, and cortisol. *Crit Care Med*. 2003 May;31(5):1382-8.
50. Barret-Conner E, Knaw KT, Yen SS. A prospective study of dehydroepiandrosterone sulfate, mortality and cardiovascular disease. *N Engl J Med*. 1986 Dec 11; 315(24):1519-24.



Mulder JW, Frissen PH, Kirjnen P, et al. Dehydroepiandrosterone as predictor for progression to AIDS in asymptomatic HIV-infected men. *J Infect Dis*. 1992; 165(3):413-418.



52. Yasushi M, Hirofumi Y, Michihiro Y, Yuki M, Koichi N, et al. Plasma levels of dehydroepiandrosterone sulfate are decreased in patients with chronic heart failure in proportion to the severity. *J Clin Endocrinol Metab.* 2000 May; 85(5):1834-40.
53. Nagai T, Noda Y, Nozaki A, Nabeshima T. Neuroactive steroid and stress response. *Nihon Shinkei Seishin Yakurigaku Zasshi.* 2001 Nov;21(5):157-62.
54. van den Beld AW, Bots ML, Janssen JA, Pols HA, Lamberts SW, Grobbee DE. Endogenous hormones and carotid atherosclerosis in elderly men. *Am J Epidemiol.* 2003 Jan 1;157(1):25-31.
55. Solerte SB, Fioravanti M, Vignati G, Giustina A, Cravello L, Ferrari E. DHEA sulfate enhances natural killer cell cytotoxicity in humans via locally generated immunoreactive insulin-like growth factor I. *J Clin Endocrinol Metab.* 1999 Sep;84(9):3260-7.
56. Khorram O, Vu L, Yen SS. Activation of immune function by dehydroepiandrosterone (DHEA) in age-advanced men. *J Gerontol A Biol Sci Med Sci.* 1997 Jan;52(1):M1-7.
57. Assan R, Robel P, Baulieu EE. Dehydroepiandrosterone (DHEA) for diabetic patients? *Eur J Endocrinol.* 1996 Jul; 135(1):37-8.
58. Casson PR, Hornsby PJ, Buster JE. Adrenal androgens, insulin resistance, and cardiovascular disease. *Semin Reprod Endocrinol.* 1996 Feb;14(1):29-34.
59. Beer NA, Jakubowicz DJ, Matt DW, Beer RM, Nestler JE. Dehydroepiandrosterone reduces plasma plasminogen activator inhibitor type 1 and tissue plasminogen activator antigen in men. *Am J Med Sci.* 1996 May;311(5):205-10
60. Casson PR, Anderson RN, Herrod HG, et al. Oral dehydroepiandrosterone in physiologic doses modulates immune function in postmenopausal women. *Am J Obstet Gynecol.* 1993 Dec; 169(6):1536-9.
61. Chang DM, Lan JL, Lin HY, Luo SF. Dehydroepiandrosterone treatment of women with mild to moderate systemic lupus erythematosus: a multicenter randomized, double-blind, placebo-controlled trial. *Arthritis Rheum.* 2002 Nov; 46(11):2924-7.
62. Gelato MC. Aging and immune function: a possible role for growth hormone. *Horm Res.* 1996;45(1-2):46-9.
63. Sacco M, Valenti G, Corvi Mora P, Wu FC, Ray DW. DHEA, a selective glucocorticoid receptor antagonist: its role in immune system regulation and metabolism. *J Endocrinol Invest.* 2002;25(10 Suppl):81-2.
64. Bradlow HL, Sepkovic DW. Diet and breast cancer. *Ann NY Acad Sci.* 2002 Jun;963:247-67.
65. Mei JJ, Hursting SD, Perkins SN, Phang JM. p53-independent inhibition of nitric oxide generation by cancer preventive interventions in ex vivo mouse peritoneal macrophages. *Cancer Lett.* 1998 Jul 17;129(2):191-7.



D'Ambrosio SM, Gibson-D'Ambrosio RE, Wani G, et al. Modulation of Ki67, p53 and Rbeta expression in normal, premalignant and malignant human oral epithelial cells by chemopreventive agents. *Anticancer Res.* 2001 Sep-Oct;21(5):3229- 35.



67. Weber E, Moore MA, Bannasch P. Phenotypic modulation of hepatocarcinogenesis and reduction in N-nitrosomorpholine-induced hemangiosarcoma and adrenal lesion development in Sprague-Dawley rats by dehydroepiandrosterone. *Carcinogenesis*. 1988 Jul;9(7):1191-5.
68. Prough RA, Lei XD, Xiao GH, Wu HQ, Geoghegan TE, Webb SJ. Regulation of cytochrome P450 by DHEA and its anticarcinogenic action. *Ann NY Acad Sci*. 1995 Dec 29;774:187-99.
69. Schwartz AG, Pashko LL. Cancer prevention with DHEA and nonandrogenic structural analogs. *J Cell Biochem Suppl*. 1995;22:210-217.
70. Inano H, Ishii-Ohba H, Suzuki K, Yamanouchi H, Onoda M, Wakabayashi K. Chemoprevention by dietary dehydroepiandrosterone against promotion / progression phase of radiation-induced mammary tumorigenesis in rats. *J Steroid Biochem and Mol Biol*. 1995 Jul; 54(1- 2):47-53.
71. Poetschke HL, Klug DB, Hursting SD, Richie ER. The effect of chemoprotective steroids on thymocyte and thymic epithelial cell development. *FASEB Journal*. 1999; 13(4):A623.
72. Greenwald P, Kelloff GJ, Boone CW, McDonald SS. Genetic and cellular changes in colorectal cancer: proposed targets of chemoprotective agents. *Cancer Epidemiol Biomarkers Prev*. 1995 Oct-Nov; 4(7):691-702.
73. Melvin WS, Boros LG, Muscarella P, et al. Dehydroepiandrosterone-sulfate inhibits pancreatic carcinoma cell proliferation in vitro and in vivo. *Surgery*. 1997 Apr;121(4):392-7.
74. Hursting SD, Perkins SN, Haines DC, Ward JM, Phang JM. Chemoprevention of spontaneous tumorigenesis in p53 knock-out mice. *Cancer Res*. 1995 Sep; 15;55(18):3949-53.
75. Ledochowski M, Murr C, Jager M, Fuchs D. Dehydroepiandrosterone, ageing and immune activation. *Exp Gerontol*. 2001 Nov; 36:1739-47.
76. Metzger C, Bannasch P, Mayer D. Enhancement and phenotypic modulation of N-nitrosomorpholine-induced hepatocarcinogenesis by dehydroepiandrosterone. *Cancer Lett*. 1997 Dec 23;121(2):125-31.
77. Moore MA, Weber E, Thornton M, Bannasch P. Sex-dependent, tissue-specific opposing effects of dehydroepiandrosterone on initiation and modulation stages of liver and lung carcinogenesis induced by dihydroxy-di-n-propylnitrosamine in F344 rats. *Carcinogenesis*. 1988 Aug; 9(8):1507-9.
78. Williams JR. The effects of dehydroepiandrosterone on carcinogenesis, obesity, the immune system and aging. *Lipids*. 2000 Mar; 35(3):325-31.
79. Orner GA, Mathews C, Hendricks JD, Carpenter HM, Bailey GS, Williams DE. Dehydroepiandrosterone is a complete hepatocarcinogen and potent tumor promoter in the absence of peroxisome proliferation in rainbow trout. *Carcinogenesis*. 1995 Dec;16(12):2893-8.



Jozuka H, Jozuka E, Suzuki M, Takeuchi S, Takatsu Y. Psycho-neuro-immunological treatment of hepatocellular carcinoma with major depression. *Curr Med Res Opin*. 2003;19(1):59-63.



81. Kavanaugh C, Green JE. The use of genetically altered mice for breast cancer prevention studies. *J Nutr.* 2003 Jul; 133(7 Suppl):2404S-2409S.
82. Regelson W, Loria R, Kalimi M. Dehydroepiandrosterone (DHEA) I: immunologic action. *Ann NY Acad Sci.* 1994 May 31;719:553-563.
83. Green JE, Shibata MA, Shibata E, et al. 2-Difluoromethylornithine and dehydroepiandrosterone inhibit mammary tumor progression but not mammary or prostate tumor initiation in C3(1)/SV40 T/t-antigen transgenic mice. *Cancer Res.* 2001 Oct 15;61(20):7449-55.
84. Perkins SN, Hursting SD, Kim K, Poetschke K, Heather L, Richie ER. Mechanisms underlying the anti-lymphoma activity of dehydroepiandrosterone: studies in murine thymocytes and murine T-cell hybridoma cells. *Cancer Epidemiology Biomarkers & Prevention.* 2002; 11(10):1233s.
85. Perkins SN, Hursting SD, Haines DC, James SJ, Miller BJ, Phang JM. Chemoprevention of spontaneous tumorigenesis in nullizygous p53-deficient mice by dehydroepiandrosterone and its analog 16alpha-fluoro-5-androsten-17-one. *Carcinogenesis.* 1997 May;18(5):989-94.
86. Perkins SN. Dietary modulation of cell cycle regulators. NCI grant. Federal research in progress (FRP). NDN 049- 0652-1518-9.
87. Hsu HC. Dehydroepiandrosterone (DHEA) sulfotransferase gene expression in human hepatocellular carcinoma: an age-dependent prognostic factor. *Proc Am Assoc Cancer Res.* 1995;36:208.
88. Osawa E, Hakajima A, Yoshida S, et al. Chemoprevention of precursors to colon cancer by dehydroepiandrosterone (DHEA). *Life Sci.* 2002 Apr 19; 70(22):2623-30.
89. Yang S, FuZ, Wang F, Cao Y, Han R. Antimutagenic activity of dehydroepiandrosterone. *Zhonghua Zhong Liu Za Zhi.* 2002 Mar; 24(2):137-40.
90. Bulbrook RD, Hayward JL, Spicer CC. Relation between urinary androgen and corticoid excretion and subsequent breast cancer. *Lancet.* 1971 Aug 21; 2(7721):395- 98.
91. Eaton NE, Reeves GK, Appleby PN, Key TJ. Endogenous sex hormones and prostate cancer: a quantitative review of prospective studies. *Br J Cancer.* 1999 Jun;80(7):930-4.
92. Vatten LJ, Ursin G, Ross RK, et al. Androgens in serum and the risk of prostate cancer: a nested case-control study from the Janus serum bank in Norway. *Cancer Epidemiol Biomarkers Prev.* 1997 Nov;6(11):967-9.
93. Stahl F, Schnorr D, Pilz C, Dorner G. Dehydroepiandrosterone (DHEA) levels in patients with prostatic cancer, heart disease, and under surgery stress. *Exp Clin Endocrinol.* 1992; 99(2):68-70.
94. Schatzl G, Madersbacher S, Thurnher M, et al. High-grade prostate cancer is associated with low serum testosterone levels. *Prostate.* 2001 Apr;47(1):52-8.



Schatzl G, Reiter WJ, Thurnher M, et al. Endocrine patterns in patients with benign and malignant prostatic diseases. *Prostate.* 2000 Aug;44(3):219-24.



96. Huot RI, Shain SA. Differential metabolism of dehydroepiandrosterone sulfate and estrogen conjugates by normal or malignant AXC/SSh rat prostate cells and effects of these steroid conjugates on cancer cell proliferation in vitro. *J Steroid Biochem.* 1988 Jun;29(6):617-21.
97. McCormick DL, Rao KV. Chemoprevention of hormone-dependent prostate cancer in the Wistar- Unilever rat. *Eur Urol.* 1999 May;35(5- 6):464-7.
98. Ponholzer A, Plas E, Schatzl G, Jungwirth A, Maderbacher S. Association of DHEA- S and estradiol serum levels to symptoms of aging men. *Aging Male.* 2002 Dec; 5(4):233-8.
99. Sun Y, Mao M, Sun L, Feng Y, Yang J, Shen P. Treatment of osteoporosis in men using dehydroepiandrosterone sulfate. *Chin Med J. (Engl)* 2002; 115(3):402-4.
100. Wallace MB, Lim J, Cutler A, Bucci L. Effects of dehydroepiandrosterone vs androstenedione supplementation in men. *Med Sci Sports Exerc.* 1999 Dec; 31(12):1788-92.
101. Miyamoto H, Marwah P, Marwah A, Lardy H, Chang C. 3 beta-acetoxyandrost- 1,5-diene-17-ethylene ketal functions as a potent antiandrogen with marginal agonist activity. *Proc Natl Acad Sci (USA).* 2003 Apr 15; 100(8):4440-4.
102. Greenwald P. Cancer risk factors for selecting cohorts for large scale chemo prevention trials. *J Cell Biochem Suppl.* 1996;25:29-36.
103. Reiter WJ, Schatzl G, Zeiner A, Pycha A, Merberger M. Dehydroepiandrosterone in the treatment of erectile dysfunction in patients with different organic etiologies. *Urol Res.* 2001 Aug; 29(4):278-81.
104. Reiter WJ, Pycha A, Schatzl G. Dehydroepiandrosterone in the treatment of erectile dysfunction: a prospective, double-blind, randomized, placebo-controlled study. *Urology.* 1999 Mar;53(3):590-94.
105. Steel N. Dehydroepiandrosterone and aging. *Age Ageing.* 1999 Mar;28(2):89-91.
106. Cutting CW, Hunt C, Nisbet JA, Bland JM, Dalglish AG, Kirby RS. Serum insulin-like growth factor-1 is not a useful marker of prostate cancer. *BJU Int.* 1999 Jun;83(9):996-9.
107. Woodson K, Tangrea JA, Pollak M, et al. Serum insulin-like growth factor I: tumor marker or etiologic factor? A prospective study of prostate cancer among Finnish men. *Cancer Res.* 2003 Jul 15; 63(14):3991-4.
108. Wan JM, Istfan NW, Ye SL, Bistran BR. Insulin-like growth factor-1 is not mitogenic for the Walker-256 carcinosarcoma. *Life Sci.* 1995 Jan 27;56(10):747-56.
109. Sonntag WE, Lynch C, Thornton P, Khan A, Bennett S, Ingram R. The effects of growth hormone and IGF-1 deficiency on cerebrovascular and brain aging. *J Anat.* 2000 Nov;197 Pt 4:575-85.
110. Haden ST, Glowacki J, Hurwitz S, Rosen C, LeBoff MS. Effects of age on serum dehydroepiandrosterone sulfate, IGF-I, and IL-6 levels in women. *Calcif Tissue Int.* 2000 ;66(6):414-8.



111. Ravaglia G, Forti P, Maioli F, et al. Body composition, sex steroids, IGF-1, and bone mineral status in aging men. *J Gerontol A Biol Sci Med Sci*. 2000 Sep;55(9):M516-21.
112. Calo L, Castrignano R, Davis PA, et al. Role of insulin-like growth factor-I in primary osteoporosis: a correlative study. *J Endocrinol Invest*. 2000 Apr;23(4):223-7
113. Carro E, Trejo JL, Gomez-Isla T, LeRoith D, Torres-Aleman I. Serum insulin-like growth factor-I regulates brain amyloid- B levels. *Nat Med*. 2002 Dec;8(12):1390-7.
114. Ruiz-Torres A, Soares de Meo Kirzner M. Aging and longevity are related to growth hormone/insulin-like growth factor-I secretion. *Gerontology*. 2002 Nov; 48(6):401-7.
115. Yoshida S, Honda A, Matsuzaki Y, et al. Antiproliferative action of endogenous dehydroepiandrosterone metabolites on human cancer cell lines. *Steroids*. 2003 Jan;68(1):73-83.
116. Simoncini T, Mannella P, Fornari L, Varone G, Caruso A, Genazzani AR. Dehydroepiandrosterone modulates endothelial nitric oxide synthesis via direct genomic and nongenomic mechanisms. *Endocrinology*. 2003 Aug;144(8):3449-55.
117. Postmenopausal hormone therapy: cardiovascular risks. *Prescrire Int*. 2003 Apr;12(64):65-9.
118. Jusko WJ, Blum RA, Meno-Tetang, Guy ML, Schwartz KE. Effects of oral dehydroepiandrosterone on single dose pharmacokinetics or oral prednisone and cortisol suppression in normal women. *J Clin Pharmacol*. 2001;41(11):1195-1205.
119. Bernardi F, Pieri M, Stomati M, et al. Effect of different hormonal replacement therapies on circulating allopregnanolone and dehydroepiandrosterone levels in postmenopausal women. *Gynecol Endocrinol*. 2003 Feb;17(1):65-77.
120. Takayanagi R, Goto K, Suzuki S, Tanaka S, Shimoda S, Nawata H. Dehydroepiandrosterone (DHEA) as a possible source for estrogen formation in bone cells: correlation between bone mineral density and serum DHEA-sulfate concentration in postmenopausal women, and the presence of aromatase to be enhanced by 1.25-dihydroxyvitamin D3 in human osteoblasts. *Mech Ageing Dev*. 2002 Apr 30;123(8):1107-14.
121. Genazzani AD, Stomati M, Strucchi C, Puccetti S, Luisi S, Genazzani AR. Oral dehydroepiandrosterone supplementation modulates spontaneous and growth hormone-releasing hormone-induced growth hormone and insulin-like growth factor-1 secretion in early and late postmenopausal women. *Fertil Steril*. 2001 Aug;76(2):241-8.
122. Kalimi M, Regelson W, eds. *The Biological Role of Dehydroepiandrosterone (DHEA)*. Berlin:Walter de Gruyter; 1990.
123. Legrain S, Massien C, Lahlou N, et al. Dehydroepiandrosterone replacement administration: pharmacokinetic and pharmacodynamic studies in healthy elderly subjects. *J Endocrinol Metab*. 2000 Sep;85(9):3208-17.



124. Baulieu EE, Thomas G, Legrain S, et al. Dehydroepiandrosterone (DHEA), DHEA sulfate, and aging: contribution of the DHEAge Study to a sociobiomedical issue. *Proc Natl Acad Sci USA*. 2000 Apr 11;97(8):4279-84.
125. Tode T, Kikuchi Y, Hirata J, Kita T, Nakata H, Nagata I. Effect of Korean red ginseng on psychological functions in patients with severe climacteric syndromes. *Int J Gynaecol Obstet*. 1999 Dec;67(3):169-74.
126. Copeland JL, Consitt LA, Tremblay MS. Hormonal responses to endurance and resistance exercise in females aged 19-69 years. *J Gerontol A Biol Sci Med Sci*. 2002 Apr;57(4):B158-65.
127. Tissandier O, Peres G, Fiet J, Piette F. Testosterone, dehydroepiandrosterone, insulin-like growth factor 1, and insulin in sedentary and physically trained aged men. *Eur J Appl Physiol*. 2001 Jul;85(1- 2):177-84.
128. Bonnefoy M, Patricot MC, Lacour JR, Rahmani A, Berthouze S, Kostka T. Relation between physical activity, muscle function and IGF-1, testosterone and DHEAS concentrations in the elderly. *Rev Med Interne*. 2002 Oct;23(10):819-27.
129. Ando S, Rubens R, Rottiers R. Androgen plasma levels in male diabetics. *J Endocrinol Invest*. 1985;7:21-4.
130. Barrett-Conner E. Lower endogenous androgen levels and dyslipidemia in men with noninsulin-dependent diabetes mellitus. *Ann Intern Med*. 1992;117:807-11.
131. Thomas N, Morris HA, Scopacasa F, Wishart JM, Need AG. Relationships between age, dehydroepiandrosterone sulphate and plasma glucose in healthy men. *Age Ageing*. 1999 Mar;28(2):217-20.
132. Johnson R. Abnormal testosterone: epitestosterone ratios after DHEA supplementation. *Clin Chemistry*. 1999; 45:163-4.
133. Salek FS, Bigos KL, Kroboth PD. The influence of hormones and pharmaceutical agents on DHEA and DHEA-S concentrations: a review of clinical studies. *J Clin Pharmacol*. 2002 Mar;42(3):247-66.
134. Moore TJ, Psaty BM, Furberg CD. Time to act on drug safety. *JAMA*. 1998 May 20; 279(19):1571-3.
135. Kruuse C, Thomsen LL, Birk S, Olesen J. Migraine can be induced by sildenafil without changes in middle cerebral artery diameter. *Brain*. 2003 Jan;126(Pt 1):241-7.
136. Azarbal B, Mirocha J, Shah PK, Cerek B, Kaul S. Adverse cardiovascular events associated with the use of Viagra®. *J Am Col Cardiol*. 2000; 35 (Suppl A): 553A- 554A.
137. Meno-Tetang GM, Blum RA, Schwartz KE, Jusko WJ. Effects of oral prasterone (dehydroepiandrosterone) on single-dose pharmacokinetics of oral prednisone and cortisol suppression in normal women. *J Clin Pharmacol*. 2001 Nov; 41(11):1195- 205.
138. Gennari R, Alexander JW. Arginine, glutamine, and dehydroepiandrosterone reverse the immunosuppressive effect of prednisone during gut-derived sepsis. *Crit Care Med*. 1997 25(7):1207-14.



139. Petri MA, Lahita RG, Van Vollenhoven RF, et al. Effects of prasterone on corticosteroid requirements of women with systemic lupus erythematosus; a double-blind, randomized, placebo-controlled trial. *Arthritis Rheum.* 2002 Jul; 46(7):1820-9.
140. Zietz B, Hrach S, Scholmerich J, Straub RH. Differential age-related changes of hypothalamus-pituitary-adrenal axis hormones in healthy women and men: role of interleukin-6. *Exp Clin Endocrinol Diabetes.* 2001;109(2):93-101.
141. Straub RH, Konecna L, Hrach S, et al. Serum dehydroepiandrosterone (DHEA) and DHEA sulfate are negatively correlated with serum interleukin-6 (IL-6), and DHEA inhibits IL-6 secretion from mononuclear cells in man: possible link between endocrinosenescence and immunosenescence. *J Endocrinol Metab.* 1998 Jun; 83(6):2012-7.
142. Straub RH, Lehle K, Herfarth H, et al. Dehydroepiandrosterone in relation to other adrenal hormones during an acute inflammatory stressful disease state compared with chronic inflammatory disease: role of interleukin-6 and tumor necrosis factor. *Eur J Endocrinol.* 2002 Mar; 146(3):365-74.
143. Vogl D, Falk W, Dorner M, Scholmerich J, Straub RH. Serum levels of pregnenolone and 17-hydroxypregnenolone in patients with rheumatoid arthritis and systemic lupus erythematosus: relation to other adrenal hormones. *J Rheumatol.* 2003 Feb;30(2):269-75.
144. Cutolo M, Straub RH, Foppiani L, et al. Adrenal gland hypofunction in active polymyalgia rheumatica; effect of glucocorticoid treatment on adrenal hormones and interleukin-6. *J Rheumatol.* 2002 Apr; 29(4):748-56.
145. Andus T, Klebl F, Rogler G, Bregenzner N, Scholmerich J, Straub RH. Patients with refractory Crohn's disease or ulcerative colitis respond to dehydroepiandrosterone: a pilot study. *Aliment Pharmacol Ther.* 2003 Feb; 17(3):409-14.
146. Straub RH, Scholmerich J, Zietz B. Replacement therapy with DHEA plus corticosteroids in patients with chronic inflammatory diseases – substitutes of adrenal and sex hormones. *Z Rheumatol.* 2002; 59:Suppl 2:108-118.
147. Osorio A, Vara-Thorbeck R, Rosell J, Osorio C, Ortega E, Ruiz-Requena E. Dehydroepiandrosterone sulfate and growth axis hormones in patients after surgery. *World J Surg.* 2002 Sep;26(9):1079-82. Epub 2002 Aug 16.
148. Canbaz S, Ege T, Sunar H, Cikirikcioglu M, Acipayam M, Duran E. The effects of cardiopulmonary bypass on androgen hormones in coronary artery bypass surgery. *J Int Med Res.* 2002 Jan-Feb; 30(1):9-14.
149. National Institute of Mental Health. Depression. Available at: <http://www.nimh.nih.gov/publicat/depression.com>. Accessed January 13, 2004.



150. Wolkowitz OM, Reus VI. Neurotransmitters, neurosteroids and neurotrophins: new models of the pathophysiology and treatment of depression. *World J Biol Psychiatry.* 2003 Jul;4(3):98-102.
151. Young AH, Gallagher P, Porter RJ. Elevation of the cortisol-dehydroepiandrosterone ratio in drug-free depressed patients. *Am J Psychiatry.* 2002 Jul;159(7):1237-9.



152. Giordano R, DiVito L, Lanfranco F, et al. Elderly subjects show severe impairment of dehydroepiandrosterone sulfate and reduced sensitivity of cortisol and aldosterone response to the stimulatory effect of ACTH. *Clin Endocrinol. (Oxf)* 2001 Aug;55(2):259-65.
153. Weill-Engerer S, David JP, Sazdovitch V, et al. Neurosteroid quantification in human brain regions; comparison between Alzheimer's and nondemented patients. *J Clin Endocrinol Metab.* 2002 Nov; 87(11):5138-43.
154. Valenti G. Andropause: an imbalance between dehydroepiandrosterone (DHEA) and cortisol secretion. *J Endocrinol Invest.* 2002;25(10 suppl):25- 35.
155. Magri F, Terenzi F, Ricciardi T, et al. Association between changes in adrenal secretion and cerebral morphometric correlates in normal aging and senile dementia. *Dement Geriatr Cogn Disord.* 2000 Mar-Apr; 11(2):90-9.
156. Karishma KK, Herbert J. Dehydroepiandrosterone (DHEA) stimulates neurogenesis in the hippocampus of the rat, promotes survival of newly formed neurons and prevents corticosterone-induced suppression. *Eur J Neurosci.* 2002 Aug;16(3):445-53.
157. Strous RD, Maayan R, Lapidus R, et al. Dehydroepiandrosterone augmentation in the management of negative, depressive, and anxiety symptoms in schizophrenia. *Arch Gen Psychiatry.* 2003 Feb;60(2):133- 41.
158. Office of Technology Assessment, US Congress. *Assessing the Efficacy and Safety of Medical Technologies.* Washington, DC: Office of Technology Assessment, US Congress; 1978.
159. Jia Q, Hong MF, Cherniske S. Measurement and Quantification of 17 Ketosteroid-Sulfates as a Biomarker of Biological Age. US patent 6,326,209 B1, Dec. 4, 2001.
160. Jia Q, Hong MF, Zhao XP, Orndorff S. Quantification of urine 17-ketosteroid sulfates and glucuronides by high-performance liquid chromatography-ion trap mass spectroscopy. *Journal of Chromatography B, Biomed Sci Appl.* 2001 Jan 5; 750(1):81-91.
161. Qi Jia, Mei-Feng Hong, Zhao-Xing Pan, et al. Quantification of urine 17-ketosteroid sulfates and their age correlations. *Spectroscopy.* 2002;16:171-81.

Page	1 (/Magazine/2004/3/cover_dhea/Page-01)	
2 (/Magazine/2004/3/cover_dhea/Page-02)	3 (/Magazine/2004/3/cover_dhea/Page-03)	
4 (/Magazine/2004/3/cover_dhea/Page-04)	5 (/Magazine/2004/3/cover_dhea/Page-05)	

